Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans
NCT07646080Phase 2Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 2 trial of toripalimab, anlotinib in dermatofibrosarcoma protuberans (DFSP). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimabanlotinib
03
Conditions
dermatofibrosarcoma protuberans (DFSP)
Beyond the preview
Go deeper on NCT07646080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646080.